Q1 Earnings Forecast for MDGL Issued By B. Riley

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Stock analysts at B. Riley issued their Q1 2025 EPS estimates for Madrigal Pharmaceuticals in a note issued to investors on Monday, November 4th. B. Riley analyst M. Mamtani forecasts that the biopharmaceutical company will earn ($3.34) per share for the quarter. B. Riley has a “Neutral” rating and a $236.00 price objective on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($25.19) per share. B. Riley also issued estimates for Madrigal Pharmaceuticals’ Q3 2025 earnings at ($2.86) EPS and Q4 2025 earnings at ($2.46) EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($4.92) earnings per share for the quarter, topping the consensus estimate of ($6.94) by $2.02. The company had revenue of $62.18 million during the quarter, compared to analysts’ expectations of $34.60 million. During the same quarter in the previous year, the company earned ($5.34) EPS.

Other equities analysts have also recently issued research reports about the stock. Citigroup dropped their price target on shares of Madrigal Pharmaceuticals from $382.00 to $371.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. UBS Group upped their target price on shares of Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald reissued a “neutral” rating on shares of Madrigal Pharmaceuticals in a research report on Friday, October 11th. StockNews.com raised Madrigal Pharmaceuticals to a “sell” rating in a research report on Saturday, October 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $390.00 target price on shares of Madrigal Pharmaceuticals in a research note on Tuesday, October 22nd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Madrigal Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $347.33.

Madrigal Pharmaceuticals Trading Up 0.2 %

NASDAQ MDGL opened at $338.22 on Wednesday. Madrigal Pharmaceuticals has a 12 month low of $133.99 and a 12 month high of $345.04. The company has a current ratio of 5.98, a quick ratio of 5.93 and a debt-to-equity ratio of 0.15. The stock’s fifty day moving average price is $232.32 and its 200-day moving average price is $245.11. The stock has a market cap of $7.38 billion, a P/E ratio of -13.49 and a beta of -0.46.

Insiders Place Their Bets

In other news, CEO William John Sibold sold 6,363 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $243.83, for a total transaction of $1,551,490.29. Following the completion of the sale, the chief executive officer now owns 55,887 shares of the company’s stock, valued at $13,626,927.21. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO William John Sibold sold 6,363 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $243.83, for a total transaction of $1,551,490.29. Following the completion of the sale, the chief executive officer now owns 55,887 shares of the company’s stock, valued at $13,626,927.21. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Richard S. Levy sold 5,000 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $300.94, for a total value of $1,504,700.00. Following the completion of the transaction, the director now directly owns 11,012 shares in the company, valued at approximately $3,313,951.28. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 22.80% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in MDGL. Avoro Capital Advisors LLC raised its stake in Madrigal Pharmaceuticals by 5.7% during the 2nd quarter. Avoro Capital Advisors LLC now owns 2,055,555 shares of the biopharmaceutical company’s stock worth $575,884,000 after acquiring an additional 111,111 shares during the period. Paulson & CO. Inc. lifted its stake in shares of Madrigal Pharmaceuticals by 4.2% during the 2nd quarter. Paulson & CO. Inc. now owns 1,850,000 shares of the biopharmaceutical company’s stock valued at $518,296,000 after buying an additional 75,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Madrigal Pharmaceuticals by 6.0% in the 1st quarter. Vanguard Group Inc. now owns 1,668,806 shares of the biopharmaceutical company’s stock worth $445,638,000 after buying an additional 94,064 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Madrigal Pharmaceuticals by 106.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 803,213 shares of the biopharmaceutical company’s stock worth $214,491,000 after buying an additional 414,484 shares in the last quarter. Finally, Fiera Capital Corp bought a new stake in Madrigal Pharmaceuticals during the second quarter valued at about $32,335,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.